Pseudomyxoma peritonei medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arising from mucinous tumors of the appendix and less commonly from ovary and colon. Pseudomyxoma peritonei symptoms include abdominal distention, bloating, hernia, and infertility. It is a very uncommon tumor with an incidence of 0.1 people per 100,000 per year, slightly more common in the female gender with a median age of 50 years at the time of diagnosis. Prognosis is good in general. Pseudomyxoma peritonei is histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA). Mainstay of treatment is cytoreduction surgery combined with hyperthermic intraperitoneal chemoperfusion (HIPEC).

Medical Therapy

Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapy with mitomycin at 42°C.^[1]^[2]^[3]

References

↑ Chen, Chin-Fan; Huang, Che-Jen; Kang, Wan-Yi; Hsieh, Jan-Sing (2008). “Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)”. World Journal of Surgical Oncology. 6 (1): 118. doi:10.1186/1477-7819-6-118. ISSN 1477-7819.
↑ Sugarbaker, Paul H (2006). “New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?”. The Lancet Oncology. 7 (1): 69–76. doi:10.1016/S1470-2045(05)70539-8. ISSN 1470-2045.
↑ Vaira M, Cioppa T, DE Marco G, Bing C, D’Amico S, D’Alessandro M, Fiorentini G, DE Simone M (2009). “Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience”. In Vivo. 23 (4): 639–44. PMID 19567401.

Overview